Journey Medical (DERM) Asset Writedowns and Impairment (2020 - 2026)

Journey Medical has reported Asset Writedowns and Impairment for 7 years, with the latest figure at $30000.0 in Q1 2026.

• For the quarter ending Q1 2026, Asset Writedowns and Impairment fell 84.62% year-over-year to $30000.0; the trailing twelve-month figure through Mar 2026 stood at -$376000.0 (down 153.33% YoY), and the FY2025 full-year result was -$211000.0, down 140.89% from the prior year.
• Asset Writedowns and Impairment for Q1 2026 stood at $30000.0, up from -$41000.0 in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $3.1 million in Q2 2023, with the low at -$2.8 million in Q3 2023.
• Historically, Asset Writedowns and Impairment has averaged $221294.1 across 5 years, with a median of $55000.0 in 2022.
• The largest YoY upside for Asset Writedowns and Impairment was 10038.71% in 2023 against a maximum downside of 5149.09% in 2023.
• Journey Medical's Asset Writedowns and Impairment stood at $274000.0 in 2022, then jumped by 867.52% to $2.7 million in 2023, then plunged by 111.58% to -$307000.0 in 2024, then jumped by 86.64% to -$41000.0 in 2025, then jumped by 173.17% to $30000.0 in 2026.
• The last three Asset Writedowns and Impairment figures came in at $30000.0 (Q1 2026), -$41000.0 (Q4 2025), and $76000.0 (Q3 2025), per Business Quant data.